Compare Stocks: NNVC, IMUX, NRXP, and UNCY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMUX Immunic	$9.37 -13.6%	$13.98	$5.06 ▼ $17.43	$147.90M	1.41	332,253 shs	660,267 shs
NNVC NanoViricides	$1.51 -1.3%	$1.37	$0.85 ▼ $2.23	$38.55M	1.66	540,389 shs	315,998 shs
NRXP NRx Pharmaceuticals	$3.16 -4.8%	$3.50	$1.62 ▼ $5.05	$136.82M	2.19	605,389 shs	550,715 shs
UNCY Unicycive Therapeutics	$4.81 -3.0%	$5.21	$3.71 ▼ $8.74	$138.16M	1.79	768,419 shs	693,652 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMUX Immunic	-13.56%	-7.41%	-43.07%	-37.82%	+5.64%
NNVC NanoViricides	-1.31%	+25.83%	+18.90%	+16.15%	+4.86%
NRXP NRx Pharmaceuticals	-4.82%	-5.67%	-8.41%	-11.24%	+10.88%
UNCY Unicycive Therapeutics	-3.02%	+0.63%	-9.93%	-41.41%	+20.85%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMUX Immunic	$9.37 -13.6%	$13.98	$5.06 ▼ $17.43	$147.90M	1.41	332,253 shs	660,267 shs
NNVC NanoViricides	$1.51 -1.3%	$1.37	$0.85 ▼ $2.23	$38.55M	1.66	540,389 shs	315,998 shs
NRXP NRx Pharmaceuticals	$3.16 -4.8%	$3.50	$1.62 ▼ $5.05	$136.82M	2.19	605,389 shs	550,715 shs
UNCY Unicycive Therapeutics	$4.81 -3.0%	$5.21	$3.71 ▼ $8.74	$138.16M	1.79	768,419 shs	693,652 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMUX Immunic	-13.56%	-7.41%	-43.07%	-37.82%	+5.64%
NNVC NanoViricides	-1.31%	+25.83%	+18.90%	+16.15%	+4.86%
NRXP NRx Pharmaceuticals	-4.82%	-5.67%	-8.41%	-11.24%	+10.88%
UNCY Unicycive Therapeutics	-3.02%	+0.63%	-9.93%	-41.41%	+20.85%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMUX Immunic	3.00	Buy	$47.25	404.27% Upside
NNVC NanoViricides	3.00	Buy	$6.00	297.35% Upside
NRXP NRx Pharmaceuticals	2.43	Hold	$34.50	991.77% Upside
UNCY Unicycive Therapeutics	2.57	Moderate Buy	$18.75	289.81% Upside

Current Analyst Ratings Breakdown

Latest NNVC, IMUX, NRXP, and UNCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/14/2026	NRXP NRx Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
9/10/2026	IMUX Immunic	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$45.00
9/10/2026	IMUX Immunic	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$22.00
9/4/2026	UNCY Unicycive Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/1/2026	IMUX Immunic	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/26/2026	IMUX Immunic	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/26/2026	NRXP NRx Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/26/2026	NRXP NRx Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/25/2026	NRXP NRx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/20/2026	UNCY Unicycive Therapeutics	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Speculative Buy	$13.00 ➝ $15.00
8/19/2026	UNCY Unicycive Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMUX Immunic	N/A	N/A	N/A	N/A	($0.55) per share	N/A
NNVC NanoViricides	N/A	N/A	N/A	N/A	$0.66 per share	N/A
NRXP NRx Pharmaceuticals	$3.39M	40.31	N/A	N/A	($0.54) per share	-5.85
UNCY Unicycive Therapeutics	$680K	197.00	N/A	N/A	$1.41 per share	3.41

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMUX Immunic	-$97.17M	-$4.38	N/A	N/A	N/A	N/A	-157.89%	-107.88%	11/12/2026 (Estimated)
NNVC NanoViricides	-$8.29M	-$0.43	N/A	N/A	N/A	N/A	-87.90%	-78.69%	N/A
NRXP NRx Pharmaceuticals	-$28.62M	-$0.55	N/A	N/A	N/A	-691.81%	N/A	-63.92%	11/13/2026 (Estimated)
UNCY Unicycive Therapeutics	-$26.56M	-$1.75	N/A	2.23	N/A	N/A	-91.50%	-61.47%	11/11/2026 (Estimated)

Latest NNVC, IMUX, NRXP, and UNCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	NRXP NRx Pharmaceuticals	-$0.1067	-$0.44	-$0.3333	-$0.44	$1.33 million	$1.10 million
8/12/2026	Q2 2026	UNCY Unicycive Therapeutics	-$0.4710	-$0.06	+$0.4110	-$0.06	$22.22 million	N/A
8/11/2026	Q2 2026	IMUX Immunic	-$1.16	-$0.80	+$0.36	-$0.80	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMUX Immunic	N/A	N/A	N/A	N/A	N/A
NNVC NanoViricides	N/A	N/A	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
UNCY Unicycive Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMUX Immunic	N/A	5.05	5.05
NNVC NanoViricides	N/A	3.44	2.47
NRXP NRx Pharmaceuticals	N/A	0.86	0.86
UNCY Unicycive Therapeutics	N/A	3.81	3.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMUX Immunic	51.82%
NNVC NanoViricides	10.30%
NRXP NRx Pharmaceuticals	4.27%
UNCY Unicycive Therapeutics	40.42%

Insider Ownership

Company	Insider Ownership
IMUX Immunic	5.49%
NNVC NanoViricides	3.60%
NRXP NRx Pharmaceuticals	6.40%
UNCY Unicycive Therapeutics	6.03%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMUX Immunic	95	13.64 million	12.90 million	Optionable
NNVC NanoViricides	7	25.53 million	14.92 million	Optionable
NRXP NRx Pharmaceuticals	29	43.30 million	40.53 million	Optionable
UNCY Unicycive Therapeutics	22	27.85 million	26.18 million	Not Optionable

NNVC, IMUX, NRXP, and UNCY Headlines

Recent News About These Companies

UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit

4 hours ago | prnewswire.com

Kaplan Fox Encourages Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Investors to Contact the Firm Before the Lead Plaintiff Deadline on November 2, 2026

September 23 at 1:45 PM | theglobeandmail.com

UNCY Investor Alert: Unicycive Therapeutics, Inc. Securities Class Action Notice - Contact Levi & Korsinsky

September 23 at 10:09 AM | prnewswire.com

Kaplan Fox Announces a Securities Class Action Filed Against Unicycive Therapeutics, Inc. (UNCY) - Lead Plaintiff Deadline is November 2, 2026

September 23 at 7:40 AM | newsfilecorp.comN

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

September 22 at 7:33 PM | globenewswire.com

ROSEN, A TOP RANKED LAW FIRM, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

September 22 at 6:31 PM | newsfilecorp.comN

UNCY EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026

September 22 at 5:08 PM | newsfilecorp.comN

UNCY Deadline Alert: SueWallSt Reminds Unicycive Therapeutics, Inc. (UNCY) Investors of Securities Class Action Deadline on November 2, 2026

September 22 at 11:11 AM | globenewswire.com

UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

September 22 at 10:02 AM | globenewswire.com

UNCY stock rises after a class action filing and a reverse split

September 21 at 7:04 PM | ad-hoc-news.deA

ROSEN, A TOP-RANKED LAW FIRM, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

September 21 at 6:26 PM | newsfilecorp.comN

Deadline Alert: Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

September 21 at 2:10 PM | globenewswire.com

Kaplan Fox Alerts Investors of Unicycive Therapeutics, Inc. (UNCY) with Significant Losses to a Securities Class Action Deadline on November 2, 2026

September 21 at 9:55 AM | newsfilecorp.comN

Financial Survey: Phathom Pharmaceuticals (NASDAQ:PHAT) versus Unicycive Therapeutics (NASDAQ:UNCY)

September 21 at 8:45 AM | americanbankingnews.com

Unicycive Therapeutics stock holds at USD 4.80

September 20, 2026 | ad-hoc-news.deA

UNCY UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026

September 20, 2026 | newsfilecorp.comN

Robbins LLP Urges UNCY Stockholders Who Lost Money Investing in Unicycive Therapeutics, Inc. to Contact the Firm for Information About Leading the Class Action

September 18, 2026 | businesswire.com

UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit

September 18, 2026 | prnewswire.com

ROSEN, A LEADING NATIONAL FIRM, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

September 18, 2026 | globenewswire.com

UNCY SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026

September 18, 2026 | newsfilecorp.comN

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Receives Consensus Recommendation of "Moderate Buy" from Analysts

September 7, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNVC, IMUX, NRXP, and UNCY Company Descriptions

Immunic NASDAQ:IMUX

$9.37 -1.47 (-13.56%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$9.41 +0.04 (+0.44%)

As of 08:21 AM Eastern

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

NanoViricides NYSE:NNVC

$1.51 -0.02 (-1.31%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$1.51 +0.00 (+0.20%)

As of 08:29 AM Eastern

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

NRx Pharmaceuticals NASDAQ:NRXP

$3.16 -0.16 (-4.82%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$3.11 -0.05 (-1.61%)

As of 08:28 AM Eastern

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

Unicycive Therapeutics NASDAQ:UNCY

$4.81 -0.15 (-3.02%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$4.77 -0.04 (-0.83%)

As of 07:55 AM Eastern

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NNVC, IMUX, NRXP, and UNCY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NNVC, IMUX, NRXP, and UNCY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NNVC, IMUX, NRXP, and UNCY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNVC, IMUX, NRXP, and UNCY Company Descriptions

Immunic NASDAQ:IMUX

NanoViricides NYSE:NNVC

NRx Pharmaceuticals NASDAQ:NRXP

Unicycive Therapeutics NASDAQ:UNCY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NNVC, IMUX, NRXP, and UNCY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NNVC, IMUX, NRXP, and UNCY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NNVC, IMUX, NRXP, and UNCY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNVC, IMUX, NRXP, and UNCY Company Descriptions

Immunic NASDAQ:IMUX

NanoViricides NYSE:NNVC

NRx Pharmaceuticals NASDAQ:NRXP

Unicycive Therapeutics NASDAQ:UNCY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools